Mesoblast Earnings Call: Ryoncil Momentum, Pipeline Upside

Mesoblast Limited ((AU:MSB)) has held its Q2 earnings call. Read on for the main highlights of the call.

Mesoblast’s latest earnings call struck an upbeat tone, with management emphasizing strong early traction for Ryoncil, exceptionally high margins, and a fortified balance sheet. While executives acknowledged heavier R&D and SG&A spending and execution risks around manufacturing and regulatory filings, the overall message was that commercial, clinical, and financial momentum is firmly positive.

Ryoncil launch underpins revenue surge

Ryoncil, launched in April 2025, delivered $49.0M in net product revenue in the first half of FY 2026, accounting for roughly 95.5% of Mesoblast’s $51.3M total revenue. Management guided to full‑year Ryoncil sales of $110M–$120M, implying a sharp step‑up in the second half as demand builds.

Gross margins highlight attractive economics

The company reported a gross margin of 93%, with gross profit excluding amortization around $44.2M for the period. Direct selling costs of just $7.7M against Ryoncil revenue underscore the high profitability potential once fixed costs and overhead are absorbed.

Broad access and fast uptake for Ryoncil

Commercial adoption is advancing quickly, with 49 treatment centers onboarded and 30 having Ryoncil on formulary. Coverage now spans payers representing more than 280M lives, including Medicaid in all states and major commercial plans, backed by a permanent J‑code effective from October 1.

Market share goals in pediatric GVHD

Management is targeting around 20% penetration of the pediatric market by the end of the first fiscal year, based on an estimated 375‑patient base. They see a realistic peak share near 40% and note that 64 centers account for 94% of the pediatric transplant population, supporting rapid market capture.

Balance sheet strength and financing flexibility

Mesoblast ended December with $130M in cash and access to a $125M nondilutive credit facility, of which $75M has already been drawn. The remaining $50M tranche can be accessed through June 2026, providing optional liquidity with a relatively low cost of capital and no prepayment penalties.

Revascor moves toward full BLA filing

For Revascor in patients supported with LVADs, data from a 159‑patient trial and a supportive 30‑patient study showed about an 80% reduction in major bleeding and hospitalizations over 12 months. The therapy also reduced early mortality risk from right heart failure, and Mesoblast now plans a full BLA submission for this indication next quarter.

Chronic back pain program advances

Rexlemestrocel‑L for chronic low back pain has completed a 404‑patient Phase III trial, with a 300‑patient confirmatory study under way and enrollment expected to finish by March or April 2026. The FDA has confirmed that a 12‑month pain reduction endpoint is approvable, supporting a data readout and BLA filing targeted for 2027.

Adult GVHD label expansion opportunity

Mesoblast is preparing to initiate a pivotal trial in adult severe steroid‑refractory GVHD in collaboration with the NIH‑funded BMT CTN network, pending central IRB sign‑off. The adult GVHD market is roughly three times larger than the pediatric segment, representing a meaningful potential extension of Ryoncil’s franchise.

Net loss narrows as cost discipline emerges

Despite heavy investment, net loss improved to $40.2M in the first half of FY 2026, compared with $48.0M a year earlier. Management said operating cash use, which totaled $30.3M in the half, should decline in the second half as Ryoncil revenues grow and spending becomes more disciplined.

R&D spending surges with late‑stage pipeline

Reported R&D expenses jumped to $46.2M from $5.1M, though last year’s figure was depressed by a $23M inventory provision reversal. On a normalized basis, R&D roughly doubled and a half, driven by the LVAD, back pain, and GVHD programs and by manufacturing and regulatory preparation for upcoming BLAs.

Higher SG&A reflects launch build‑out

Sales, general, and administrative costs climbed to $28.5M from $18.0M, reflecting the build‑out of commercial infrastructure to support the Ryoncil rollout. Management framed these costs as front‑loaded investments intended to support broader reimbursement, center onboarding, and future label expansions.

Revenue concentration and liquidity watchpoints

With Ryoncil representing about 95.5% of first‑half revenue, Mesoblast remains heavily dependent on a single product. While cash levels are solid and the credit facility provides a buffer, ongoing cash burn and the deadline to draw the remaining tranche by June 2026 are key items for investors to monitor.

Manufacturing and regulatory execution risks

Mesoblast is still completing commercial manufacturing validation and potency assay work for its upcoming BLAs, even though Ryoncil is already produced at an approved facility. The company also flagged ongoing discussions with regulators over labeling nuances for Revascor, which could affect the breadth of its eventual indication.

Near‑term cost pressure from growth investments

Management acknowledged that heavy upfront spending on commercialization and late‑stage trials has pushed operating expenses higher in the short term. The thesis is that sustained revenue growth, margin leverage, and eventual regulatory approvals across multiple programs will convert this investment into durable cash generation.

Guidance and outlook emphasize growth and de‑risking

The company reaffirmed FY 2026 guidance, including Ryoncil net revenues of $110M–$120M, around 20% pediatric penetration by year‑end, and a 93% gross margin profile. Mesoblast expects operating cash use to fall in the second half, the subordinated royalty facility to be repaid by mid‑2026, and key milestones from Revascor and rexlemestrocel‑L to progressively diversify revenue.

Mesoblast’s earnings call painted a picture of a company transitioning from a single‑product launch story toward a multi‑asset, late‑stage platform, albeit with elevated spending and execution hurdles. For investors, the combination of strong Ryoncil momentum, high margins, and a robust pipeline offers considerable upside, provided the company delivers on its regulatory and commercialization roadmap.